Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
P/E ratio for Exscientia plc (EXAI)
P/E ratio as of 2023: -4.29
According to Exscientia plc's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.29. At the end of 2022 the company had a P/E ratio of -4.61.
P/E ratio history for Exscientia plc from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -4.29 |
| 2022 | -4.61 |
| 2021 | -48.32 |
| 2020 | -78.63 |
| 2019 | -297.02 |